Sichenzia Ross Ference LLP代表Aegis Capital Corp.作为独家账簿管理人完成对Avinger，Inc.普通股的1,440万美元要约收购
Press Release – New York, NY – February 2, 2021 – Sichenzia Ross Ference LLP today announced that it represented Aegis Capital Corp. as sole bookrunner in an underwritten offering of 10,000,000 shares of the common stock of Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), at a price of $1.44 per share. The gross proceeds of the offering were approximately $14.4 million, prior to deducting underwriting discounts and commissions and estimated offering expenses.
新闻稿–纽约，纽约– 2021年2月2日– Sichenzia Ross Ference LLP今天宣布代表Aegis Capital Corp.作为独家账簿管理人，承销Avinger，Inc.（NASDAQ：AVGR）1000万股普通股，这是一家商业阶段的医疗设备公司，以每股1.44美元的价格销售第一个也是唯一的基于血管内图像引导的导管系统，用于诊断和治疗外周动脉疾病（PAD）。扣除承销折扣和佣金以及估计的发行费用之前，发行的总收益约为1,440万美元。
这些股票是根据先前向美国证券交易委员会提交并宣布为有效的货架注册声明提出的。
Sichenzia Ross Ference LLP团队由合伙人Gregory Sichenzia，Darrin M. Ocasio和Jay Yamamoto以及其合伙人Matthew Siracusa领导。
